A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression

Thyroid

Volumn 24, Issue 8, 2014, Pages 1241-1250

  Gunda, Viswanath ^a   Frederick, Dennie T ^a   Bernasconi, Maria J ^a   Wargo, Jennifer A ^b   Parangi, Sareh ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GAMMA INTERFERON; GRANZYME B; HLA A2 ANTIGEN; MESSENGER RNA; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NY ESO 1 ANTIGEN; PROTEIN; T LYMPHOCYTE RECEPTOR; AZACITIDINE; CTAG1B PROTEIN, HUMAN; GRANZYME; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DRUG EXPOSURE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; THYROID CANCER CELL LINE; THYROID PAPILLARY CARCINOMA; TUMOR XENOGRAFT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; COCULTURE; CYTOLOGY; CYTOPLASM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOTHERAPY; LYMPHOCYTE; METABOLISM; METASTASIS; METHYLATION; POLYMERASE CHAIN REACTION; PROCEDURES; SCID MOUSE; THYROID TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; AZACITIDINE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOPLASM; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPHOCYTES; MEMBRANE PROTEINS; METHYLATION; MICE; MICE, SCID; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL; RNA, MESSENGER; THYROID NEOPLASMS;

EID: 84904663277     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0680     Document Type: Article

References (44)

1. Simard EP, Ward EM, Siegel R, Jemal A 2012 Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 62:118-128.
2. Brown RL 2008 Standard and emerging therapeutic approaches for thyroid malignancies. Semin Oncol 35:298-308. (Pubitemid 351790737)
3. Harris PJ, Bible KC 2011 Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin Investig Drugs 20:1357-1375.
4. Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S 2012 Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 36:1247-1254.
5. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719.
6. Wong KK 2009 Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov 4:28-35.
7. Mandala M, Voit C 2013 Targeting BRAF in melanoma: Biological and clinical challenges. Crit Rev Oncol Hematol 87:239-255.
8. Fedorenko IV, Paraiso KH, Smalley KS 2011 Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol 82:201-209.
9. Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K, Speiser D, Peters S, Rimoldi D, Michielin O 2013 Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600Emutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res 19:5749-5757.
10. Callahan MK, Wolchok JD 2013 At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 94:41-53.
11. Menzies AM, Long GV 2013 New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol 5:278-285.
12. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT 2002 Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22-32. (Pubitemid 35398862)
13. Caballero OL, Chen YT 2009 Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Scie 100: 2014-2021.
14. Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E, Knuth A, Chen YT, Old LJ 2006 NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 95:1-30. (Pubitemid 44088423)
15. Hemminger JA, Ewart Toland A, Scharschmidt TJ, Mayerson JL, Kraybill WG, Guttridge DC, Iwenofu OH 2013 The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas. Mod Pathol 26:282-288.
16. Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, Schadendorf D, Buttner P, Garbe C, Pawelec G 2012 Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clinl Oncol 30:1835-1841.
17. Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jager E, Lubbert M 2010 The DNA demethylating agent 5-aza-2-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 34:899-905.
18. Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, Kuzushima K, Kondo Y, Sekido Y, Kawatsura H, Narita Y, Yoshida J 2008 The DNA demethylating agent 5-aza-2- deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 122:2542-2553. (Pubitemid 351590488)
19. Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong- On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH, Nguyen DM, Rosenberg SA, Schrump DS 2001 Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 24: 151-161. (Pubitemid 32183061)
20. Wargo JA, Robbins PF, Li Y, Zhao Y, El-Gamil M, Caragacianu D, Zheng Z, Hong JA, Downey S, Schrump DS, Rosenberg SA, Morgan RA 2009 Recognition of NY-ESO- 1 + tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother 58:383-394.
21. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA 2011 Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917-924.
22. Ebert LM, MacRaild SE, Zanker D, Davis ID, Cebon J, Chen W 2012A cancer vaccine induces expansion of NYESO- 1-specific regulatory T cells in patients with advanced melanoma. PloS One 7:e48424.
23. Karbach J, Neumann A, Brand K, Wahle C, Siegel E, Maeurer M, Ritter E, Tsuji T, Gnjatic S, Old LJ, Ritter G, Jager E 2012 Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. Clin Cancer Res 18:5449-5459.
24. Maio M, Coral S, Sigalotti L, Elisei R, Romei C, Rossi G, Cortini E, Colizzi F, Fenzi G, Altomonte M, Pinchera A, Vitale M 2003 Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 88:748-754. (Pubitemid 36207818)
25. Milkovic M, Sarcevic B, Glavan E 2006 Expression of MAGE tumor-associated antigen in thyroid carcinomas. Endocr Pathol 17:45-52. (Pubitemid 43997972)
26. Ruschenburg I, Kubitz A, Schlott T, Korabiowska M, Droese M 1999 MAGE-1, GAGE-1/-2 gene expression in FNAB of classic variant of papillary thyroid carcinoma and papillary hyperplasia in nodular goiter. Int J Mol Med 4:445-448.
27. Gunda V, Cogdill AP, Bernasconi MJ, Wargo JA, Parangi S 2013 Potential role of 5-Aza-2-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer. Surgery 154:1456-1462.
28. Blank CU, Hooijkaas AI, Haanen JB, Schumacher TN 2011 Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol Immunother 60:1359-1371.
29. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA 2012 Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18: 1386-1394.
30. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA 2010 Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70:5213-5219.
31. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S 2011 Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 16:296-309.
32. Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V, Parangi S 2009A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid 19:1077-1084.
33. Serrano A, Tanzarella S, Lionello I,Mendez R, Traversari C, Ruiz-Cabello F, Garrido F 2001 Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2-deoxycytidine treatment. Int J Cancer 94:243-251. (Pubitemid 32911420)
34. Mora-Garcia Mde L, Duenas-Gonzalez A, Hernandez- Montes J, De la Cruz-Hernandez E, Perez-Cardenas E, Weiss-Steider B, Santiago-Osorio E, Ortiz-Navarrete VF, Rosales VH, Cantu D, Lizano-Soberon M, Rojo-Aguilar MP, Monroy-Garcia A 2006 Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J Transl Med 4:55.
35. Sapkota B, Hill CE, Pollack BP 2013 Vemurafenib enhances MHC induction in BRAF homozygous melanoma cells. Oncoimmunology 2:e22890.
36. Gottesman MM 2002 Mechanisms of cancer drug resistance. Annu Rev Med 53:615-627. (Pubitemid 34177898)
37. Ganss R, Arnold B, Hammerling GJ 2004 Mini-review: overcoming tumor-intrinsic resistance to immune effector function. Eur J Immunol 34:2635-2641. (Pubitemid 39430139)
38. Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE 2012 Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY- 142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res 18: 2056-2065.
39. Gild ML, Bullock M, Robinson BG, Clifton-Bligh R 2011 Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 7:617-624.
40. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA 2011 Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 364:2507-2516.
41. Kyi C, Postow MA 2013 Checkpoint blocking antibodies in cancer immunotherapy. FEBS Letters 588:368-376.
42. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME 2008 Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299-308. (Pubitemid 351430867)
43. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R 2006 Phase I study of adoptive T-cell therapy using antigen-specific CD8 + T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24:5060-5069. (Pubitemid 46631410)
44. Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, Eberlein TJ 1995 Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 13:1939-1949.